ZVSA
ZyVersa Therapeutics, Inc.
Key Financials
Net Income
$-24952378
↓ 165.1%
Operating Income
$-25492690
↓ 179.0%
EPS (Diluted)
$-4.18
↑ 50.7%
Total Liabilities
$12.7M
↑ 5.4%
Total Assets
$347901.00
↓ 98.3%
Shareholders' Equity
$-12386786.00
↓ 245.4%
Cash & Equivalents
$928389.00
N/A
Operating Cash Flow
$-5114381.00
↑ 32.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 7/16/2026 | View on SEC |
| 8-K | 7/10/2026 | View on SEC |
| 10-Q | 5/13/2026 | View on SEC |
| 10-K | 3/31/2026 | View on SEC |
| 8-K | 3/5/2026 | View on SEC |
| 8-K | 12/3/2025 | View on SEC |
| 8-K | 11/19/2025 | View on SEC |
| 10-Q | 11/19/2025 | View on SEC |
| NT 10-Q | 11/14/2025 | View on SEC |
| 8-K | 10/15/2025 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ZVSA |
| Company Name | ZyVersa Therapeutics, Inc. |
| CIK | 1859007 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | OTC |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 908-370-5102 |